May 8, 2024 Am I a Genus? The Amgen case and its impact on genus patenting for biologics By Ella Hilder
April 5, 2023 NIH Refuses to Employ “March-In” Rights in Petition to Lower Cancer Drug Costs By Olivia Santiago
March 7, 2023 New FDA Final Guidance May Pump the Brakes on Software Designed to Assist and Improve Doctor’s Clinical Decision Making By Avi Strauss
April 29, 2022 Where We Are Now on the COVID-19 TRIPS Proposal—Is an IP Waiver the Right Way to Address Vaccine Inequity? By Kelsey Price
December 11, 2021 Patent Subject Matter Eligibility in the Biotechnology Industry By Mikaella Evaristo
November 17, 2021 Damned If We Don’t and… Also Damned If We Don’t: A Look into the History of Vaccine Mandates and the Future of the COVID-19 Vaccine By Eleesya Cordes
March 22, 2021 What Comes Next for Clearview AI After the Recent Ban by the Canadian Government By Elad Jerusalem